BAO PHARMA-B

Shanghai Bao Pharmaceuticals opened lower but rallied during the morning session, rising from an intraday low of HKD 16.33 to HKD 16.92, a gain of approximately 3.6%. The move was driven by the company's frequent share repurchases, with over 10 buybacks announced since late June at average prices between HKD 17.38 and HKD 19.98, indicating management's view that the stock is undervalued. Additionally, the NMPA approved the company's clinical trial for synthetic biology ulinastatin BJ044, boosting sentiment around the pipeline. However, the stock remains deeply under pressure: YTD is down 75.72%, the price is 91.79% below the 52-week high of HKD 206, and at HKD 16.92, it trades below the MA20 of HKD 17.40 and MA60 of HKD 18.76. The fundamental backdrop remains challenging, with Q4 2025 net loss of HKD 117.99 million widening 12.51% YoY, revenue of only HKD 3.98 million, and a net profit margin of -2961%.

Shanghai Bao Pharmaceuticals (2659.HK) had a sharp decline in the morning session, opening at HKD 18.29 and rapidly weakening to close at HKD 17.14, down 4.67% from the previous close of HKD 17.98, with an intraday high of HKD 18.68 and low of HKD 17.02 (a range of ~9.7%). The company has disclosed a series of share repurchases from late June to early August 2026, with prices ranging from HKD 17.31 to HKD 19.98, indicating management support. However, fundamental pressure persists: Q4 2025 revenue of HKD 3.98 million grew 60.43% YoY, but net loss of HKD 117.99 million widened 12.51% YoY, with EPS of -HKD 0.4035 and a net profit margin of -2961.29%. The current price of HKD 17.14 is 91.68% below the 52-week high of HKD 206, and below both the 20-day MA (HKD 18.06) and 60-day MA (HKD 19.96), with a YTD decline of 75.41%. Though insider purchases of ~CNY 5.34 million and the recent NMPA approval for a ulinastatin BJ044 clinical trial provide some positive catalysts.

2659.HK staged a low-open rally, closing up 5.15% at HKD 18.37, near the intraday high of HKD 18.37, after recovering from the morning low of HKD 17.36; the move was driven by the company's ongoing share repurchases (multiple monthly buybacks at average prices of HKD 17.3-19.9) and NMPA approval for clinical trials of its synthetic biology ulinastatin BJ044, though Q4 2025 net loss widened 12.51% YoY to HKD 118 million on revenue of only HKD 3.98 million, underscoring persistent losses; the stock sits 91.08% below its 52-week high of HKD 206, below the MA60 of HKD 20.12, and is down 73.64% YTD, while the PB of 3.38x suggests valuation remains a tug-of-war between losses and pipeline progress.

Bao Pharmaceuticals closed at HKD 17.60, down 4.71% from the prior close of HKD 18.47, exhibiting a rally-then-retreat pattern: opening at HKD 18.02, surging to an intraday high of HKD 18.78 in the morning session, then sliding to an afternoon low of HKD 17.37 before settling near the session bottom. The company has conducted at least 10 share repurchases in the past month, with buyback prices ranging from HKD 17.31 to HKD 19.98, yet the stock remains under pressure. Q4 2025 revenue rose 60.43% YoY to HKD 3.98 million, but net loss widened to HKD 117.99 million, with EPS of -HKD 0.4035. The stock is 91.46% below its 52-week high of HKD 206.0, trading below both its 20-day MA (HKD 18.69) and 60-day MA (HKD 21.01), while posting a YTD decline of 74.75%. However, the company received NMPA approval in June to commence trials for synthetic biology ulinastatin BJ044, offering a potential pipeline catalyst.

Shanghai Bao Pharma opened lower in the morning session at HKD 19.21, surged to an intraday high of HKD 20.12, then retreated to close at HKD 19.32, up a marginal 0.84% from the previous close of HKD 19.16. The stock remains 90.62% below its 52-week high of HKD 206, with a YTD decline of 72.28%. The session's 'surge-and-pullback' pattern was primarily driven by the company's recent series of share repurchases, conducted at prices ranging from HKD 17.31 to HKD 19.98 since hitting a 52-week low of HKD 15.67 on June 24, signaling management's confidence in valuation. In Q4 2025, operating revenue rose 60.43% YoY to HKD 3.98 million, but net loss widened 12.51% YoY to HKD 117.99 million, with EPS of -HKD 0.4035, reflecting ongoing R&D investment. The stock now holds above its 20-day MA of HKD 18.72 while facing resistance at the 60-day MA of HKD 21.28, indicating a long recovery path from the 52-week high.